On March 8, 2019 Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, reported that an abstract highlighting the preclinical data of Oraxol (HM30181A plus oral paclitaxel) in angiosarcoma has been accepted for presentation in a Poster Session at the American Association of Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2019, taking place March 29 – April 3, 2019 in Atlanta, Georgia (Press release, Athenex, MAR 8, 2019, View Source;p=RssLanding&cat=news&id=2390635 [SID1234534126]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In the angiosarcoma xenograft model, oral dosing of Oraxol resulted in dose-dependent tumor growth inhibition and subsequent increased survival. Tumor histology revealed that Oraxol greatly reduced the formation of cavernous blood-filled neoplastic vessels characteristic of angiosarcoma.
Oraxol was granted Orphan Drug Designation by the U.S. FDA for the treatment of angiosarcomas in April 2018. Athenex has commenced a Phase I clinical study evaluating Oraxol in angiosarcomas.
Details of the presentation are as follows:
Title: Effective preclinical management of angiosarcoma with oral paclitaxel (abstract #5261)
Session Category: Experimental and Molecular Therapeutics
Session: DNA Repair and Reactive Agents / HDAC / Demethylating Agents
Date: April 3, 2019 (Wednesday)
Time: 8:00am – 12:00pm ET
Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 10
The abstract for the Athenex’s poster is available on the AACR (Free AACR Whitepaper) website here.
The Orascovery platform was initially developed by Hanmi Pharmaceuticals and licensed exclusively to Athenex for all major worldwide territories except Korea, which is retained by Hanmi.
About Angiosarcoma
Angiosarcomas are a type of soft tissue sarcoma characterized by rapidly proliferating, extensively infiltrating, anaplastic cells derived from blood and lymphatic vessels. Angiosarcomas arise in various body sites, including cutaneous, soft tissue, and visceral locations. Angiosarcomas are frequently metastatic at diagnosis, with a natural history complicated by local recurrence, distant metastases, and poor overall survival. Angiosarcomas represent about 2% of soft tissue sarcomas and 5.4% of cutaneous soft tissue sarcomas.
There is no approved treatment for angiosarcoma and survival is limited with treatments currently available. However, reports in the literature of objective tumor response support the use of intravenous paclitaxel in the treatment of angiosarcoma.